Trial Outcomes & Findings for A Study for the Treatment of Alcohol Dependence (NCT NCT00804570)

NCT ID: NCT00804570

Last Updated: 2019-09-24

Results Overview

The Timeline Followback Method assesses the subject's daily drinking by means of a calendar that covers a specific time period and was used to assess the number of heavy drinking days. Heavy drinking is defined as ≥4 drinks/day for women and ≥5 drinks/day for men. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, treatment\*visit, gender\*family history, baseline, and baseline\*visit. An unstructured covariance structure was used.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

375 participants

Primary outcome timeframe

Week 16

Results posted on

2019-09-24

Participant Flow

Participant milestones

Participant milestones
Measure
LY2196044
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
once daily, orally, 16 weeks
Overall Study
STARTED
187
188
Overall Study
COMPLETED
115
94
Overall Study
NOT COMPLETED
72
94

Reasons for withdrawal

Reasons for withdrawal
Measure
LY2196044
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
once daily, orally, 16 weeks
Overall Study
Adverse Event
14
7
Overall Study
Lack of Efficacy
0
1
Overall Study
Lost to Follow-up
18
21
Overall Study
Entry criteria not met
5
5
Overall Study
Protocol Violation
12
16
Overall Study
Physician Decision
1
2
Overall Study
Sponsor decision
1
4
Overall Study
Withdrawal by Subject
21
38

Baseline Characteristics

A Study for the Treatment of Alcohol Dependence

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
LY2196044
n=187 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=188 Participants
once daily, orally, 16 weeks
Total
n=375 Participants
Total of all reporting groups
Age, Continuous
44.92 years
STANDARD_DEVIATION 10.62 • n=99 Participants
44.79 years
STANDARD_DEVIATION 10.08 • n=107 Participants
44.85 years
STANDARD_DEVIATION 10.34 • n=206 Participants
Sex: Female, Male
Female
66 Participants
n=99 Participants
66 Participants
n=107 Participants
132 Participants
n=206 Participants
Sex: Female, Male
Male
121 Participants
n=99 Participants
122 Participants
n=107 Participants
243 Participants
n=206 Participants
Race/Ethnicity, Customized
White
152 participants
n=99 Participants
134 participants
n=107 Participants
286 participants
n=206 Participants
Race/Ethnicity, Customized
Black or African American
26 participants
n=99 Participants
43 participants
n=107 Participants
69 participants
n=206 Participants
Race/Ethnicity, Customized
Asian
1 participants
n=99 Participants
1 participants
n=107 Participants
2 participants
n=206 Participants
Race/Ethnicity, Customized
American Indian or Alaska Native
0 participants
n=99 Participants
3 participants
n=107 Participants
3 participants
n=206 Participants
Race/Ethnicity, Customized
Multiple races
7 participants
n=99 Participants
7 participants
n=107 Participants
14 participants
n=206 Participants
Race/Ethnicity, Customized
Unknown/Missing
1 participants
n=99 Participants
0 participants
n=107 Participants
1 participants
n=206 Participants
Region of Enrollment
United States
187 participants
n=99 Participants
188 participants
n=107 Participants
375 participants
n=206 Participants
Years of Alcohol Use
30.64 years
STANDARD_DEVIATION 9.50 • n=99 Participants
28.60 years
STANDARD_DEVIATION 10.44 • n=107 Participants
29.53 years
STANDARD_DEVIATION 10.02 • n=206 Participants
Years of Heavy Drinking
25.06 years
STANDARD_DEVIATION 13.20 • n=99 Participants
24.83 years
STANDARD_DEVIATION 11.00 • n=107 Participants
24.94 years
STANDARD_DEVIATION 12.05 • n=206 Participants

PRIMARY outcome

Timeframe: Week 16

Population: Participants with a baseline and post-baseline value.

The Timeline Followback Method assesses the subject's daily drinking by means of a calendar that covers a specific time period and was used to assess the number of heavy drinking days. Heavy drinking is defined as ≥4 drinks/day for women and ≥5 drinks/day for men. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, treatment\*visit, gender\*family history, baseline, and baseline\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=181 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=172 Participants
once daily, orally, 16 weeks
Percentage of Heavy Drinking Days at Week 16 Endpoint
-43.02 percentage of days
Standard Error 2.09
-38.72 percentage of days
Standard Error 2.12

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants with a baseline and post-baseline value.

The Timeline Followback Method assesses the subject's daily drinking by means of a calendar that covers a specific time period and was used to assess the number of drinks consumed per day. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, treatment\*visit, gender\*family history, baseline, and baseline\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=185 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=179 Participants
once daily, orally, 16 weeks
Change From Baseline in Drinks Per Day at Week 16 Endpoint
-5.37 number of drinks/day
Standard Error 0.22
-4.66 number of drinks/day
Standard Error 0.22

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants with a baseline and post-baseline value.

The Timeline Followback Method assesses the subject's daily drinking by means of a calendar that covers a specific time period and was used to assess the percentage of days abstinent. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, treatment\*visit, gender\*family history, baseline, and baseline\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=181 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=172 Participants
once daily, orally, 16 weeks
Change From Baseline in Percentage of Days Abstinent at Week 16 Endpoint
33.49 percentage of days
Standard Error 2.05
28.12 percentage of days
Standard Error 2.09

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants with a baseline and post-baseline value.

The Timeline Followback Method assesses the subject's daily drinking by means of a calendar that covers a specific time period and was used to assess the number of drinks consumed on the days the participant drank. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, treatment\*visit, gender\*family history, baseline, and baseline\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=182 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=178 Participants
once daily, orally, 16 weeks
Change From Baseline in Drinks Per Drinking Day at Week 16 Endpoint
-3.77 number of drinks/drinking day
Standard Error 0.26
-3.38 number of drinks/drinking day
Standard Error 0.26

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants with a baseline and post-baseline value.

The Timeline Followback Method assesses the subject's daily drinking by means of a calendar that covers a specific time period and was used to assess the number of drinks consumed on heavy drinking days. Heavy drinking is defined as ≥4 drinks/day for women and ≥5 drinks/day for men. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, treatment\*visit, gender\*family history, baseline, and baseline\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=178 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=175 Participants
once daily, orally, 16 weeks
Change From Baseline in Drinks Per Heavy Drinking Day at Week 16 Endpoint
-2.61 number of drinks/heavy drinking day
Standard Error 0.26
-2.17 number of drinks/heavy drinking day
Standard Error 0.26

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants with a baseline and post-baseline value.

Cravings will be assessed using the OCDS. The OCDS is a 14-item self-rating instrument. Total scores range from 0-40. Higher scores indicate more obsessive and craving. Least Squares (LS) Mean value was controlled for treatment, site, visit, gender, history, baseline, gender\*history, treatment\*visit, baseline\*visit, gender\*treatment, gender\*treatment\*visit. Subject was treated as a random effect. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=174 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=162 Participants
once daily, orally, 16 weeks
Change From Baseline in Obsessive Compulsive Drinking Scale (OCDS) Total Score at Week 16 Endpoint
-8.64 units on a scale
Standard Error 0.51
-7.96 units on a scale
Standard Error 0.53

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants with a baseline and post-baseline value.

DrInC is a self-administered, 50-item questionnaire designed to measure adverse consequences of alcohol abuse in 5 areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. DrInC-2R provides a measurement since the last interview. Total scores range from 0-150, and higher scores indicate greater severity of symptoms. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, baseline, gender\*family history, treatment\*visit, baseline\*visit. Subject was treated as a random effect. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=148 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=136 Participants
once daily, orally, 16 weeks
Change From Baseline in Drinker Inventory of Consequences (DrInC) - Recent Consequences (DrInC-2R) Total Score at Week 16 Endpoint
-16.54 units on a scale
Standard Error 1.09
-13.53 units on a scale
Standard Error 1.11

SECONDARY outcome

Timeframe: Week 16

Population: Participants with a baseline and post-baseline value.

GGT and carbohydrate-deficient transferrin (%CDT) will be used as biochemical markers of alcohol consumption. A combination of GGT and %CDT improves the sensitivity of detecting excessive alcohol consumption as compared to either marker alone, or other traditional markers. Elevated levels indicate heavy alcoholism. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, baseline, gender\*family history, treatment\*visit, baseline\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=176 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=161 Participants
once daily, orally, 16 weeks
Ratio of Geometric Means Over Baseline in Gamma-Glutamyltransferase (GGT) Level at Week 16 Endpoint
0.85 ratio
Standard Error 0.02
0.94 ratio
Standard Error 0.02

SECONDARY outcome

Timeframe: Week 16

Population: Participants with a baseline and post-baseline value.

Gamma-Glutamyltransferase (GGT) and %CDT will be used as biochemical markers of alcohol consumption. A combination of GGT and %CDT improves the sensitivity of detecting excessive alcohol consumption as compared to either marker alone, or other traditional markers. Elevated levels indicate heavy alcoholism. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, baseline, gender\*family history, treatment\*visit, baseline\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=173 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=157 Participants
once daily, orally, 16 weeks
Ratio of Geometric Means Over Baseline in Percent Carbohydrate-Deficient Transferrin (%CDT) Level at Week 16 Endpoint
0.90 ratio
Standard Error 0.02
0.94 ratio
Standard Error 0.02

SECONDARY outcome

Timeframe: Week 16

Population: Participants with a baseline and post-baseline value.

AST is a potential biomarker for LY2196044 efficacy as decreases reflect decreased alcohol consumption. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, gender, family history, baseline, gender\*family history, treatment\*visit, baseline\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=176 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=161 Participants
once daily, orally, 16 weeks
Ratio of Geometric Means Over Baseline in Aspartate Transaminase (AST) Level at Week 16 Endpoint
0.88 ratio
Standard Error 0.02
0.94 ratio
Standard Error 0.02

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants with a baseline and post-baseline value.

The BDI-II contains 21 items that characterize how the subject was feeling in the past 2 weeks. There is a 4-point scale for each item ranging from 0 to 3 (0=no depression; 3=very depressed). Total scores range from 0-63. Higher scores indicate greater severity of depression. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, gender, family history, baseline, gender\*family history, treatment\*visit, baseline\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=185 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=179 Participants
once daily, orally, 16 weeks
Change From Baseline in Beck Depression Inventory II (BDI-II) Total Score at Week 16 Endpoint
-3.10 units on a scale
Standard Error 0.28
-2.78 units on a scale
Standard Error 0.28

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants with a baseline and post-baseline value.

BAI is a 21-item patient-completed questionnaire designed to assess the characteristics of anxiety. Participant was asked to rate how much he or she has been bothered by each symptom over the past week. Each item is rated on a 4-point scale (0=not present; 3=present in the extreme). Total scores range from 0 to 63. The higher the score, the more severe the anxiety symptoms. LS Mean value was controlled for treatment, pooled investigator, gender, family history, visit, baseline, gender\*family history, treatment\*visit, baseline\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=150 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=136 Participants
once daily, orally, 16 weeks
Change From Baseline in Beck Anxiety Inventory (BAI) Total Score at Week 16 Endpoint
-1.98 units on a scale
Standard Error 0.25
-1.54 units on a scale
Standard Error 0.26

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants with a baseline and post-baseline value.

The BIS-11 is a 30-item, self-administered impulsivity scale. Motor, cognitive, and non-planning domains are assessed and a total score is computed. This scale has previously been used in substance-abusing populations. Total scores range from 30-120. Higher scores indicate greater severity of symptoms. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, gender, family history, baseline, gender\*family history.

Outcome measures

Outcome measures
Measure
LY2196044
n=120 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=99 Participants
once daily, orally, 16 weeks
Change From Baseline in Barratt Impulsivity Scale-11 (BIS-11) Total Score at Week 16 Endpoint
-1.70 units on a scale
Standard Error 0.65
-2.95 units on a scale
Standard Error 0.69

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants with a baseline and post-baseline value.

Thoughts About Abstinence Scale was to measure participant's commitment to abstinence. It includes 3 items on a scale of 1-10: own desire to stop drinking (1=no desire to quit); own expectation of success in quitting (1=lowest expectation of success); how difficult to quit and remain abstinent (1=lowest amount of difficulty); and their goal related to alcohol use (scale of 1-7: 1=having no goal, up to total abstinence at 6 \[7 was none of 6 above\]). Least Squares (LS) Mean value was controlled for treatment, pooled investigator, gender, family history, baseline, gender\*family history.

Outcome measures

Outcome measures
Measure
LY2196044
n=123 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=100 Participants
once daily, orally, 16 weeks
Change From Baseline in Thoughts About Abstinence Scale at Week 16 Endpoint
Desire to stop drinking at this time
-0.60 units on a scale
Standard Error 0.20
-0.11 units on a scale
Standard Error 0.21
Change From Baseline in Thoughts About Abstinence Scale at Week 16 Endpoint
Expectation of success in quitting alcohol
-0.20 units on a scale
Standard Error 0.25
-0.00 units on a scale
Standard Error 0.27
Change From Baseline in Thoughts About Abstinence Scale at Week 16 Endpoint
Difficulty to quit and remain abstinent
-1.11 units on a scale
Standard Error 0.28
-0.63 units on a scale
Standard Error 0.30
Change From Baseline in Thoughts About Abstinence Scale at Week 16 Endpoint
Goal related to alcohol use
0.00 units on a scale
Standard Error 0.17
0.04 units on a scale
Standard Error 0.18

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants with a baseline and post-baseline value.

Q-LES-Q-SF is a self-report instrument that assesses the degree of enjoyment and satisfaction in daily life activities. The domains include: social relationships, living or house situation, and physical health. Total scores range from 14-70. Higher scores indicate better quality of life. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, gender, family history, visit, baseline, gender\*family history, treatment\*visit, baseline\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=150 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=133 Participants
once daily, orally, 16 weeks
Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Total Score at Week 16 Endpoint
2.85 units on a scale
Standard Error 0.56
2.08 units on a scale
Standard Error 0.59

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants with a baseline and post-baseline value.

EWPS is a self-rated work productivity scale that assesses such topics as work hours, work missed, and behaviors and feelings related to the workplace. The EWPS will be completed only by subjects who work outside the home. There are 25 items and total scores range from 0-100. Higher scores indicate poorer productivity. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, gender, family history, visit, baseline, gender\*family history, treatment\*visit, baseline\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=119 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=106 Participants
once daily, orally, 16 weeks
Change From Baseline in Endicott Work Productivity Scale (EWPS) Total Score at Week 16 Endpoint
-5.67 units on a scale
Standard Error 0.76
-6.13 units on a scale
Standard Error 0.79

SECONDARY outcome

Timeframe: Over 16 weeks

Population: Participants who took study drug and contributed PK sample.

Plasma concentrations were analyzed using population PK methodology with non-linear mixed effect modeling (NONMEM) software.

Outcome measures

Outcome measures
Measure
LY2196044
n=169 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
once daily, orally, 16 weeks
Population Pharmacokinetic (PK) - Apparent Clearance
36.5 Liter/hour (L/hr)
Standard Error 3.97

SECONDARY outcome

Timeframe: Over 16 weeks

Population: Participants who took study drug and contributed PK sample.

Plasma concentrations were analyzed using population PK methodology with non-linear mixed effect modeling (NONMEM) software.

Outcome measures

Outcome measures
Measure
LY2196044
n=169 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
once daily, orally, 16 weeks
Population Pharmacokinetic (PK) - Apparent Volume of Distribution
587 Liter (L)
Standard Error 8.38

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants who took at least one dose of study drug.

Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, baseline, treatment\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=186 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=179 Participants
once daily, orally, 16 weeks
Change From Baseline in Supine Blood Pressure (BP) at Week 16 Endpoint
Supine Systolic BP
-1.22 millimeters of mercury (mmHg)
Standard Error 0.68
-0.45 millimeters of mercury (mmHg)
Standard Error 0.69
Change From Baseline in Supine Blood Pressure (BP) at Week 16 Endpoint
Supine Diastolic BP
-1.53 millimeters of mercury (mmHg)
Standard Error 0.43
-1.08 millimeters of mercury (mmHg)
Standard Error 0.44

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants who took at least one dose of study drug.

Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, baseline, treatment\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=186 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=179 Participants
once daily, orally, 16 weeks
Change From Baseline in Supine Pulse Rate at Week 16 Endpoint
-0.16 beats per minute (bpm)
Standard Error 0.51
0.37 beats per minute (bpm)
Standard Error 0.53

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants who took at least one dose of study drug.

Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, baseline, treatment\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=148 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=135 Participants
once daily, orally, 16 weeks
Change From Baseline in QTc Fridericia's Correction Interval (QTcF) Measured by Electrocardiograms at Week 16 Endpoint
-1.90 milliseconds
Standard Error 0.86
0.18 milliseconds
Standard Error 0.90

SECONDARY outcome

Timeframe: Baseline through Week 16

Population: Participants who took at least one dose of study drug.

Percentage of participants discontinued study due to one or more AEs.

Outcome measures

Outcome measures
Measure
LY2196044
n=187 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=188 Participants
once daily, orally, 16 weeks
Percentage of Participants Discontinuation Due to Adverse Events (AEs)
7.5 percentage of participants
3.7 percentage of participants

SECONDARY outcome

Timeframe: Baseline through Week 16

Population: Participants who took at least one dose of study drug.

Percentage of participants had one or more TEAEs during treatment period. TEAE is a worsening or new occurrence of adverse event during treatment compared to baseline.

Outcome measures

Outcome measures
Measure
LY2196044
n=187 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=188 Participants
once daily, orally, 16 weeks
Percentage of Participants With Treatment-Emergent Adverse Events (TEAE)
76.5 percentage of participants
61.7 percentage of participants

SECONDARY outcome

Timeframe: Baseline, Week 16

Orthostatic BP is the BP measured within 3 minutes of standing. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, baseline, treatment\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=186 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=179 Participants
once daily, orally, 16 weeks
Change From Baseline in Orthostatic Blood Pressure (BP) at Week 16 Endpoint
Orthostatic Diastolic BP
-0.07 mmHg
Standard Error 0.27
0.25 mmHg
Standard Error 0.28
Change From Baseline in Orthostatic Blood Pressure (BP) at Week 16 Endpoint
Orthostatic Systolic BP
-1.23 mmHg
Standard Error 0.42
-0.55 mmHg
Standard Error 0.43

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants who took at least one dose of study drug.

Orthostatic pulse rate is the pulse rate measured within 3 minutes of standing. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, visit, baseline, treatment\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=186 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=179 Participants
once daily, orally, 16 weeks
Change From Baseline in Orthostatic Pulse Rate at Week 16 Endpoint
0.65 beats per minute
Standard Error 0.30
-0.09 beats per minute
Standard Error 0.31

SECONDARY outcome

Timeframe: Baseline through Week 16

Population: Participants who took at least one dose of study drug.

The revised CIWA-Ar scale measured the severity of alcohol withdrawal by rating 10 signs and symptoms: nausea; tremor; autonomic hyperactivity; anxiety; agitation; tactile, visual, and auditory disturbances; headache; and disorientation. Total scores range from 0-67. Higher scores indicate greater severity of withdrawal.

Outcome measures

Outcome measures
Measure
LY2196044
n=187 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=188 Participants
once daily, orally, 16 weeks
Number of Participants With Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar)≥10 at Any Time From Baseline Through Week 16 Endpoint
0 participants
0 participants

SECONDARY outcome

Timeframe: Baseline, Week 16

Population: Participants with a baseline and post-baseline value.

The GSRS is a clinician-administered scale used to assess upper and lower gastrointestinal physical symptoms. 15 items covering domains of abdominal pain, reflux syndrome, indigestion syndrome, diarrhea syndrome, and constipation syndrome were assessed with a 1-week recall period. Total scores range from 0-45. Higher scores indicate greater severity of symptoms. Least Squares (LS) Mean value was controlled for treatment, pooled investigator, gender, family history, visit, baseline, gender\*family history, treatment\*visit, baseline\*visit. An unstructured covariance structure was used.

Outcome measures

Outcome measures
Measure
LY2196044
n=185 Participants
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Placebo
n=179 Participants
once daily, orally, 16 weeks
Change From Baseline in Gastrointestinal Symptom Rating Scale (GSRS) Total Score at Week 16 Endpoint
0.03 units on a scale
Standard Error 0.13
-0.54 units on a scale
Standard Error 0.13

Adverse Events

LY2196044

Serious events: 4 serious events
Other events: 143 other events
Deaths: 0 deaths

Placebo

Serious events: 5 serious events
Other events: 116 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
LY2196044
n=187 participants at risk
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily (QD), orally (PO), 16 weeks
Placebo
n=188 participants at risk
once daily (QD), orally (PO), 16 weeks
Gastrointestinal disorders
Small intestinal obstruction
0.53%
1/187 • Number of events 1
0.00%
0/188
Hepatobiliary disorders
Biliary colic
0.53%
1/187 • Number of events 1
0.00%
0/188
Hepatobiliary disorders
Cholecystitis
0.00%
0/187
0.53%
1/188 • Number of events 1
Infections and infestations
Appendicitis
0.53%
1/187 • Number of events 1
0.00%
0/188
Injury, poisoning and procedural complications
Muscle strain
0.00%
0/187
0.53%
1/188 • Number of events 1
Investigations
Blood creatine phosphokinase increased
0.00%
0/187
0.53%
1/188 • Number of events 1
Investigations
Blood creatine phosphokinase mb increased
0.00%
0/187
0.53%
1/188 • Number of events 1
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
0.00%
0/187
0.53%
1/188 • Number of events 1
Psychiatric disorders
Alcoholism
0.00%
0/187
0.53%
1/188 • Number of events 1
Psychiatric disorders
Depression
0.00%
0/187
0.53%
1/188 • Number of events 1
Surgical and medical procedures
Alcohol detoxification
0.53%
1/187 • Number of events 1
0.00%
0/188

Other adverse events

Other adverse events
Measure
LY2196044
n=187 participants at risk
250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily (QD), orally (PO), 16 weeks
Placebo
n=188 participants at risk
once daily (QD), orally (PO), 16 weeks
Gastrointestinal disorders
Abdominal distension
6.4%
12/187 • Number of events 12
1.1%
2/188 • Number of events 2
Gastrointestinal disorders
Abdominal pain
10.2%
19/187 • Number of events 22
3.2%
6/188 • Number of events 6
Gastrointestinal disorders
Abdominal pain upper
5.9%
11/187 • Number of events 13
1.6%
3/188 • Number of events 4
Gastrointestinal disorders
Constipation
6.4%
12/187 • Number of events 13
1.6%
3/188 • Number of events 5
Gastrointestinal disorders
Diarrhoea
19.3%
36/187 • Number of events 39
8.5%
16/188 • Number of events 17
Gastrointestinal disorders
Dyspepsia
3.2%
6/187 • Number of events 6
5.3%
10/188 • Number of events 11
Gastrointestinal disorders
Flatulence
9.1%
17/187 • Number of events 17
4.8%
9/188 • Number of events 9
Gastrointestinal disorders
Frequent bowel movements
4.3%
8/187 • Number of events 8
0.53%
1/188 • Number of events 1
Gastrointestinal disorders
Gastrointestinal sounds abnormal
3.7%
7/187 • Number of events 8
1.6%
3/188 • Number of events 3
Gastrointestinal disorders
Nausea
13.4%
25/187 • Number of events 28
6.4%
12/188 • Number of events 12
Gastrointestinal disorders
Vomiting
5.9%
11/187 • Number of events 11
1.6%
3/188 • Number of events 3
General disorders
Fatigue
9.1%
17/187 • Number of events 20
4.8%
9/188 • Number of events 9
Infections and infestations
Upper respiratory tract infection
5.3%
10/187 • Number of events 11
3.7%
7/188 • Number of events 7
Investigations
Blood creatine phosphokinase increased
2.1%
4/187 • Number of events 4
3.2%
6/188 • Number of events 9
Metabolism and nutrition disorders
Decreased appetite
4.8%
9/187 • Number of events 10
2.7%
5/188 • Number of events 5
Musculoskeletal and connective tissue disorders
Arthralgia
1.1%
2/187 • Number of events 2
3.7%
7/188 • Number of events 7
Musculoskeletal and connective tissue disorders
Back pain
4.8%
9/187 • Number of events 9
3.7%
7/188 • Number of events 10
Nervous system disorders
Headache
5.9%
11/187 • Number of events 17
9.0%
17/188 • Number of events 20
Nervous system disorders
Somnolence
3.2%
6/187 • Number of events 6
1.1%
2/188 • Number of events 2
Psychiatric disorders
Anxiety
3.2%
6/187 • Number of events 7
1.1%
2/188 • Number of events 2
Psychiatric disorders
Libido decreased
3.2%
6/187 • Number of events 6
0.53%
1/188 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Cough
3.2%
6/187 • Number of events 6
0.53%
1/188 • Number of events 1
Vascular disorders
Hypertension
3.2%
6/187 • Number of events 6
1.6%
3/188 • Number of events 3

Additional Information

Chief Medical Officer

Eli Lilly and Company

Phone: 800-545-5979

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: GT60